Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-3-7
pubmed:abstractText
The prognosis of glioblastoma multiforme remains poor despite recent therapeutic advances. Several clinical and therapeutic factors as well as tumour characteristics have been reported as significant to survival. A more efficient determination of the prognostic factors is required to optimize individual therapeutic management. The aim of our study was to evaluate by univariate then multivariate analysis the factors that influence prognosis and particularly survival.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0942-0940
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
149
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
245-52; discussion 252-3
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed-meshheading:17273889-Adolescent, pubmed-meshheading:17273889-Adult, pubmed-meshheading:17273889-Aged, pubmed-meshheading:17273889-Aged, 80 and over, pubmed-meshheading:17273889-Brain Neoplasms, pubmed-meshheading:17273889-Chemotherapy, Adjuvant, pubmed-meshheading:17273889-Combined Modality Therapy, pubmed-meshheading:17273889-Cranial Irradiation, pubmed-meshheading:17273889-Dacarbazine, pubmed-meshheading:17273889-Disease-Free Survival, pubmed-meshheading:17273889-Female, pubmed-meshheading:17273889-Glioblastoma, pubmed-meshheading:17273889-Humans, pubmed-meshheading:17273889-Male, pubmed-meshheading:17273889-Middle Aged, pubmed-meshheading:17273889-Multivariate Analysis, pubmed-meshheading:17273889-Neoplasm, Residual, pubmed-meshheading:17273889-Prognosis, pubmed-meshheading:17273889-Radiotherapy, Adjuvant, pubmed-meshheading:17273889-Retrospective Studies
pubmed:year
2007
pubmed:articleTitle
Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients.
pubmed:affiliation
Department of Neurosurgery, Hospital Roger Salengro, University Medical Centre, Lille, France. j-mineo@chru-lille.fr
pubmed:publicationType
Journal Article